Skip to main content
. 2017 Jun 30;17(3):481–485. doi: 10.1007/s40268-017-0194-8

Fig. 1.

Fig. 1

Clinical response after four cycles of treatment in patients who switched from infliximab (RP) to the biosimilar CT-P13 versus those who continued on RP. *Defined as DAS28 <2.6 in RA/PsA patients or BASDAI <2.0 in AS patients. AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, DAS28 Disease Activity Score in 28 joints, PsA psoriatic arthritis, RA rheumatoid arthritis, RP reference product